· | Total revenue for the year was $400,000, with $275,000 coming in the fourth quarter as the Company entered the commercialization phase of its business. Sequentially, revenue in the fourth quarter increased by $250,000 from the $25,000 reported for the third quarter. |
· | The Company’s net loss for Fiscal 2013 was ($3.9) million or ($2.12) per share, compared with net loss of ($1.4) million or ($0.85) per share in the prior fiscal year. The Company’s net loss for the fourth quarter was ($811) thousand, or ($0.43) per share, compared with net loss of ($1.2) million or ($0.61) per share in the third quarter. |
· | Operating expenses totaled $4.4 million for the fiscal year ended March 31, 2013, and included the expenses of the merged company since its acquisition date of July 12, 2012. Of that amount, $829 thousand were non-cash charges for depreciation, amortization and stock compensation expense. Operating Expenses for the fourth quarter were $1.1 million, which included approximately $272 thousand for non-cash charges. This represented a reduction in operating expenses from the third quarter of Fiscal 2013, which came in at $1.3 million and included $222 thousand of non-cash charges. |
· | The operating loss for Fiscal 2013 was ($4.1) million, compared to ($2.5) million in the prior year. During the fourth quarter, the operating loss was ($848) thousand, compared to operating loss of ($717) thousand in the fourth quarter of the prior fiscal year, and ($1.3) million in the third quarter of Fiscal 2013. |
· | CollabRx ended the Fiscal Year 2013 with approximately $4 million in cash and cash equivalents. |
· | The fourth quarter of Fiscal 2013 marked the initial revenues generated by the commercial laboratory products and services of CollabRx, Inc., a data analytics company that uses cloud-based expert systems to inform healthcare decision-making. |
· | The Company formed a Pan Cancer (biomarker-focused) molecular oncology editorial board to be led by Razelle Kurzrock, M.D., who will serve as Chief Editor. The Pan Cancer board is the most recent addition among CollabRx’s existing editorial boards, which identify clinically actionable biomarkers in the context of individual cancer types such as lung cancer or melanoma. The Pan Cancer editorial board is differentiated in that it will apply a broad molecular oncology perspective in the identification of biomarkers that are clinically actionable in any cancer type. Background about the editorial board can be found on the company’s website (http://www.collabrx.com/expert-affiliations/cancer-specific-editorial-boards/pan-cancer/). |
· | Under the terms of a multi-year partnership agreement with Life Technologies Corporation (NASDAQ: LIFE), CollabRx accelerated activities during the Fiscal Fourth Quarter related to the development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies’ global cancer diagnostics activities and its laboratory developed test services business. |
· | CollabRx and Projects In Knowledge, Inc., a leading developer of point-of-care digital and mobile information tools and continuing medical education (CME/CE) programs, announced a multi-year partnership agreement to jointly distribute informational point-of-care software applications to the more than 35,000 oncologists and other clinicians in the Projects In Knowledge clinician network. |
· | CollabRx announced the formation of an editorial board for prostate cancer to be led by E. David Crawford, M.D. who will serve as Chief Editor. Dr. Crawford is the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. Dr. Crawford will lead a distinguished group of physicians from leading institutions such as Yale University, University of Michigan, Cleveland Clinic, Dana-Farber Cancer Institute, and others. |
· | CollabRx announced the formation of a Pan Cancer (biomarker-focused) molecular oncology editorial board to be led by Razelle Kurzrock, M.D., who will serve as Chief Editor. Dr. Kurzrock is Director of the Center for Personalized Therapy at UC San Diego Moores Cancer Center, Vice Chief of the Hematology-Oncology Division in the UC San Diego School of Medicine and Senior Deputy Center Director, Clinical Science, for UC San Diego Moores Cancer Center. |
|
March 31,
|
March 31,
|
||||||
|
2013
|
2012
|
||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
4,039
|
$
|
7,820
|
||||
Accounts receivable
|
250
|
0
|
||||||
Prepaid expenses and other current assets
|
102
|
56
|
||||||
Other assets of discontinued operations
|
11
|
418
|
||||||
Total current assets
|
4,402
|
8,294
|
||||||
Property and equipment, net
|
142
|
56
|
||||||
Intangible assets, net
|
1,490
|
-
|
||||||
Goodwill
|
603
|
-
|
||||||
Investment in convertible promissory note
|
345
|
312
|
||||||
Total assets
|
$
|
6,982
|
$
|
8,662
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable, accrued expenses and current liabilities
|
$
|
167
|
$
|
317
|
||||
Common stock warrant liability
|
10
|
19
|
||||||
Liabilities of discontinued operations
|
16
|
246
|
||||||
Total current liabilities
|
193
|
582
|
||||||
Deferred tax liability
|
581
|
-
|
||||||
Promissory Note
|
504
|
-
|
||||||
Total liabilities
|
1,278
|
582
|
||||||
|
||||||||
Stockholders’ equity:
|
||||||||
Preferred stock, $0.01 par value; 5,000,000 shares authorized; none issued and outstanding
|
-
|
-
|
||||||
Common stock, $0.01 par value; 50,000,000 shares authorized; 1,952,980 and 1,688,807 shares issued and outstanding at March 31, 2013 and March 31, 2012, respectively
|
19
|
17
|
||||||
Additional paid-in capital
|
130,602
|
129,052
|
||||||
Accumulated other comprehensive loss
|
(142
|
)
|
(142
|
)
|
||||
Accumulated deficit
|
(124,775
|
)
|
(120,847
|
)
|
||||
Total stockholders’ equity
|
5,704
|
8,080
|
||||||
Total liabilities and stockholders’ equity
|
$
|
6,982
|
$
|
8,662
|
||||
|
|
Three Months Ended
|
Twelve Months Ended
|
||||||||||||||
|
March 31,
|
March 31,
|
||||||||||||||
|
2013
|
2012
|
2013
|
2012
|
||||||||||||
|
||||||||||||||||
Revenue
|
$
|
250
|
$
|
-
|
$
|
300
|
$
|
--
|
||||||||
Revenue - related party
|
25
|
25
|
100
|
100
|
||||||||||||
Total revenue
|
275
|
25
|
400
|
100
|
||||||||||||
Cost of revenue
|
18
|
--
|
56
|
--
|
||||||||||||
Gross profit
|
257
|
25
|
344
|
100
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Engineering
|
243
|
--
|
568
|
--
|
||||||||||||
Research and development
|
169
|
--
|
457
|
--
|
||||||||||||
Sales and marketing
|
73
|
--
|
249
|
--
|
||||||||||||
General and administrative
|
620
|
742
|
3,165
|
2,615
|
||||||||||||
Total operating expenses
|
1,105
|
742
|
4,439
|
2,615
|
||||||||||||
Operating loss
|
(848
|
)
|
(717
|
)
|
(4,095
|
)
|
(2,515
|
)
|
||||||||
Equity in loss of unconsolidated affiliate
|
--
|
(1,545
|
)
|
--
|
(2,046
|
)
|
||||||||||
Other income (expense), net
|
10
|
12
|
39
|
18
|
||||||||||||
Loss before income tax benefit
|
(838
|
)
|
(2,250
|
)
|
(4,056
|
)
|
(4,543
|
)
|
||||||||
Income tax benefit
|
(31
|
)
|
--
|
(83
|
)
|
--
|
||||||||||
Loss from continuing operations
|
(807
|
)
|
(2,250
|
)
|
(3,973
|
)
|
(4,543
|
)
|
||||||||
Gain on sale of discontinued operations, net of taxes
|
--
|
--
|
--
|
2,930
|
||||||||||||
Income (loss) from discontinued operations, net of taxes
|
(4
|
)
|
23
|
45
|
184
|
|||||||||||
(Loss) income from discontinued operations, net of taxes
|
(4
|
)
|
23
|
45
|
3,114
|
|||||||||||
Net loss
|
(811
|
)
|
(2,227
|
)
|
(3,928
|
)
|
(1,429
|
)
|
||||||||
|
||||||||||||||||
Other comprehensive income
|
--
|
--
|
--
|
25
|
||||||||||||
Comprehensive loss
|
$
|
(811
|
)
|
$
|
(2,227
|
)
|
$
|
(3,928
|
)
|
$
|
(1,404
|
)
|
||||
|
||||||||||||||||
Net loss per share from continuing operations:
|
||||||||||||||||
Basic and diluted
|
$
|
(0.43
|
)
|
$
|
(1.33
|
)
|
$
|
(2.14
|
)
|
$
|
(2.69
|
)
|
||||
Net income per share from discontinued operations:
|
||||||||||||||||
Basic and diluted
|
$
|
-
|
$
|
0.01
|
$
|
0.02
|
$
|
1.84
|
||||||||
Total net loss per share:
|
||||||||||||||||
Basic and diluted
|
$
|
(0.43
|
)
|
$
|
(1.32
|
)
|
$
|
(2.12
|
)
|
$
|
(0.85
|
)
|
||||
|
||||||||||||||||
Weighted-average shares used in per share computation:
|
||||||||||||||||
Basic and diluted
|
1,886
|
1,689
|
1,856
|
1,689
|